Immunovant Stock Performance
| IMVT Stock | USD 18.79 1.23 6.14% |
The company retains a Market Volatility (i.e., Beta) of -1.02, which attests to a somewhat significant risk relative to the market. As the market becomes more bullish, returns on owning Immunovant are expected to decrease slowly. On the other hand, during market turmoil, Immunovant is expected to outperform it slightly. At this point, Immunovant has a negative expected return of -0.33%. Please make sure to check out Immunovant's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if Immunovant performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Immunovant has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's basic indicators remain comparatively stable which may send shares a bit higher in April 2025. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
| Begin Period Cash Flow | 376.5 M |
Immunovant |
Immunovant Relative Risk vs. Return Landscape
If you would invest 2,566 in Immunovant on December 19, 2024 and sell it today you would lose (538.00) from holding Immunovant or give up 20.97% of portfolio value over 90 days. Immunovant is currently does not generate positive expected returns and assumes 3.4339% risk (volatility on return distribution) over the 90 days horizon. In different words, 30% of stocks are less volatile than Immunovant, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Immunovant Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Immunovant's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Immunovant, and traders can use it to determine the average amount a Immunovant's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0969
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IMVT |
Estimated Market Risk
| 3.43 actual daily | 30 70% of assets are more volatile |
Expected Return
| -0.33 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.1 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Immunovant is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Immunovant by adding Immunovant to a well-diversified portfolio.
Immunovant Fundamentals Growth
Immunovant Stock prices reflect investors' perceptions of the future prospects and financial health of Immunovant, and Immunovant fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Immunovant Stock performance.
| Return On Equity | -0.74 | ||||
| Return On Asset | -0.45 | ||||
| Current Valuation | 3.02 B | ||||
| Shares Outstanding | 169.86 M | ||||
| Price To Book | 9.64 X | ||||
| EBITDA | (269.98 M) | ||||
| Cash And Equivalents | 427.2 M | ||||
| Cash Per Share | 3.66 X | ||||
| Total Debt | 138 K | ||||
| Debt To Equity | 0 % | ||||
| Book Value Per Share | 2.40 X | ||||
| Cash Flow From Operations | (214.23 M) | ||||
| Earnings Per Share | (2.62) X | ||||
| Total Asset | 666.37 M | ||||
| Retained Earnings | (825.68 M) | ||||
About Immunovant Performance
Assessing Immunovant's fundamental ratios provides investors with valuable insights into Immunovant's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Immunovant is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 124 people.Things to note about Immunovant performance evaluation
Checking the ongoing alerts about Immunovant for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Immunovant help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Immunovant generated a negative expected return over the last 90 days | |
| Immunovant has high historical volatility and very poor performance | |
| Immunovant has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (259.34 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Immunovant currently holds about 427.2 M in cash with (214.23 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.66. | |
| Immunovant has a frail financial position based on the latest SEC disclosures | |
| Roughly 58.0% of the company shares are held by company insiders |
- Analyzing Immunovant's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Immunovant's stock is overvalued or undervalued compared to its peers.
- Examining Immunovant's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Immunovant's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Immunovant's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Immunovant's stock. These opinions can provide insight into Immunovant's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Immunovant Stock Analysis
When running Immunovant's price analysis, check to measure Immunovant's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immunovant is operating at the current time. Most of Immunovant's value examination focuses on studying past and present price action to predict the probability of Immunovant's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immunovant's price. Additionally, you may evaluate how the addition of Immunovant to your portfolios can decrease your overall portfolio volatility.